Results 101 to 110 of about 46,717 (298)
Advanced NanoBiomed Research, EarlyView.Cancer cell membrane‐based nanoparticles (CCM‐NPs) and cancer cell‐derived small extracellular vesicles (CsEVs) are emerging as promising drug delivery systems for targeted cancer treatment. Advances in nanotechnology have paved the way for innovative drug delivery systems that enhance the effectiveness of cancer treatment.
Wei Zhang +4 more
wiley +1 more source
Platelets, 2019 Drug-induced Immune thrombocytopenia (DIT) is a common complication of several medications, including commonly used antibiotics. The most widely studied DIT is caused by quinine. In DIT, antibodies predominantly bind to the platelet membrane glycoprotein
Zohra Ahmadi +3 more
doaj +1 more source
Bulk fluid phase behaviour of colloidal platelet-sphere and platelet-polymer mixtures [PDF]
, 2012 Using a geometry-based fundamental measure density functional theory, we calculate bulk fluid phase diagrams of colloidal mixtures of vanishingly thin hard circular platelets and hard spheres. We find isotropic-nematic phase separation with strong broadening of the biphasic region upon increasing the pressure.
arxiv +1 more source
Arthritis &Rheumatology, EarlyView.Objective Takayasu arteritis (TAK) and giant cell arteritis (GCA), the most common forms of large‐vessel vasculitis (LVV), can result in serious morbidity. Understanding the molecular basis of LVV should aid in developing better biomarkers and treatments. Methods Plasma proteomic profiling of 184 proteins was performed in two cohorts. Cohort 1 included
Robert T. Maughan +15 more
wiley +1 more source
Lysosomal Membrane Glycoproteins in Platelets [PDF]
Thrombosis and Haemostasis, 1992 Hans Clevers, Marcel J Metzelaar
openaire +4 more sources
Engineering antibodies with cancer‐associated binding sites
BMEMat, EarlyView.This review describes antibodies that perform direct/indirect roles in cancer treatment by binding to effective targets and discusses how antibodies kill tumors and modulate tumor microenvironment through these targets. The classification of expression systems for antibody production is summarized to guide appropriate selection based on different ...
Yinqi Tian +4 more
wiley +1 more source
PLoS Genetics, 2019 CD36 is a platelet membrane glycoprotein whose engagement with oxidized low-density lipoprotein (oxLDL) results in platelet activation. The CD36 gene has been associated with platelet count, platelet volume, as well as lipid levels and CVD risk by genome-
Namrata Madan +5 more
doaj +1 more source
Journal of Cellular and Molecular Medicine, Volume 26, Issue 23, Page 5743-5754, December 2022., 2022 Abstract Vascular endothelial growth factor‐C (VEGF‐C) binds to receptor vascular endothelial growth factor receptor‐3 (VEGFR‐3) expressed on lymphatic endothelial and melanoma cells. Binding of VEGF‐C to VEGFR‐3 enhances receptor phosphorylation that activates mitogen‐activated protein kinase (MAP‐K) and phosphatidylinositol‐3‐kinase (PI3K).
Yvette N. Hlophe, Anna M. Joubert
wiley +1 more source
Neonatal Intracranial Hemorrhage with a Dramatic Outcome Due to Maternal Anti CD36 Antibodies
Reports, 2019 Fetal/neonatal allo-immune thrombocytopenia (FNAIT) results from maternal immunization against fetal platelet-specific antigens (HPA) inherited from the father. Most cases involve HPA located on glycoproteins (GP) IbIX, IaIIa and IIbIIIa.
Gérald Bertrand +5 more
doaj +1 more source
Current and novel biomarkers in cardiogenic shock
European Journal of Heart Failure, EarlyView.A summary of current and novel biomarkers and their potential stages of release in cardiogenic shock. The diagram illustrates the proposed release of the biomarkers during the different stages of cardiogenic shock: progression from cardiac dysfunction/stress, through to inflammation and end‐organ dysfunction.
Victor Galusko +5 more
wiley +1 more source